ClinicalTrials.gg
RecruitingNCT07397975TRUSTING-WP4Updated Feb 9, 2026

Speech-based Assessment of Relapse Risk in People With Psychosis

An observational study in Psychotic Disorder, sponsored by Philipp Homan. Recruiting at 7 sites in 6 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Philipp Homan · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Psychotic Disorders with a site in Switzerland — 10 open to participants now, 11 under way, 3 of them phase 3. Psychotic Disorders · Switzerland.

Started
2026
with 2 others
Observational
5 of 25
1 open now
Primary completion
2029-01
later than 9 of 10 live
Registered
25th of 25
by date

Among the 25 studies in Psychotic Disorders with a site in Switzerland, this one is one of 3 that started in 2026, is one of 5 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 25th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

10 of the 25 studies in Psychotic Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Psychotic Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.

Read the detailed description

This project follows a prospective, exploratory, observational design with a non-randomized, two-arm structure, including a group of individuals with psychosis at risk of relapse and a healthy control group. As a multicenter, international research project, it will assess the usability and feasibility of speech data collection across 6 different languages (English, German, French, Dutch, Czech and Turkish) and healthcare systems, ensuring its applicability in diverse clinical environments.

Speech and self-report data will be collected weekly for a year using a finalized smartphone application, ensuring consistency and feasibility in real-world clinical settings. The recordings will be securely transferred to an external platform for AI-based analysis, preventing any direct impact on clinical decision-making and maintaining the study's observational nature.

To ensure data integrity and reliability, a Human-in-the-Loop (HITL) quality control process is implemented after each speech recording session:

Initial Data Review: a designated reviewer (HITL1) checks the audio quality and accuracy of automated transcripts stored securely in the Trusted Secure Database (TSD) system in Norway. They correct transcription errors and flag anomalies such as poor audio quality to maintain data accuracy for analysis.

Risk Assessment and Decision Suggestion: a second reviewer (HITL2) evaluates the data by: (i) assessing speech characteristics relevant to relapse risk based on raw response data and performance scores (e.g., story recall accuracy); (ii) providing an independent relapse risk estimate, without access to the automated AI-generated risk assessment, (iii) classify the participant as belonging to either the psychosis or healthy control group, and (iv) suggesting a clinical decision, which is recorded for research purposes but not shared with the treating clinician.

Apart from this Fast Diagnostic Loop, where a clinical decision will be made, an exploratory component will be incorporated to identify and validate new speech markers associated with relapse. This New Marker Discovery Loop will involve the search of additional speech features associated with relapse beyond the standard markers. The goal is to discover novel speech markers that may improve our understanding of relapse mechanisms and potentially serve as predictive or diagnostic tools for future clinical use.

For the 1-year follow-up period, participants will attend a total of three study visits. These visits will occur at the following time points: Visit 0: Baseline visit, Visit 1: 6 months post-baseline (±10 days), and Visit 2: 12 months post-baseline (±10 days). During these visits, participants from both groups will undergo assessments aiming to evaluate the usability and trustworthiness of the procedure and to assess various functional and quality-of-life outcomes.

03

Conditions studied

  • Psychotic Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants at risk of relapse will be recruited from clinical settings while in a stable phase of partial or full remission. Depending on the site, eligible individuals may be either inpatients nearing discharge or outpatients under ongoing care. If the treating clinician considers the patient's mental state sufficiently stable, the study information and consent process may be initiated during inpatient care, prior to discharge. For outpatients, participants may be contacted by phone, or the study can be presented during routine outpatient or day clinic visits.

Healthy participants will be recruited through community outreach, advertisements, and volunteer registries from universities and hospitals. healthy participants will be selected to match individuals with psychosis based on key characteristics such as age and sex in each site.

Eligibility criteria

Healthy participants Inclusion Criteria:

  • Between 18 and 65 years old.
  • Subjects must be able to provide (IC).
  • Participants must have provided signed informed consent prior to enrollment.
  • Participants should not take prescription drugs regularly.
  • Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish.
  • Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection.
  • Must be able to comply with the study schedule and procedures.

Healthy participants Exclusion Criteria:

  • Any history of major diseases (e.g., cardiovascular, neurological, metabolic, renal, hepatic, respiratory or speech disorders).
  • Recreational drug use or psychiatric disorders due to use of alcohol.
  • Depression, anxiety, or other psychiatric disorders.
  • Family history of depression, anxiety, or other psychiatric disorders.
  • Individuals who are not able or willing to understand the purpose and details of the study.

Individuals with psychosis Inclusion Criteria:

  • Between 18 and 65 years old.
  • Diagnoses include psychotic disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, psychosis not otherwise specified).
  • First visit must be during remission phase (baseline measurement).
  • Current positive symptoms rated 3 (mild) or lower on all of these Brief Psychiatric Symptom Scale (BPRS) items: hallucinatory behavior, unusual thought content, conceptual disorganization.
  • Must be able to comply with the study schedule and procedures.
  • Subjects must be able to provide IC.
  • Participants must have provided signed informed consent prior to enrollment.
  • Native or equivalent fluency in speaking and understanding one of the following languages: English, German, Dutch, French, Czech or Turkish.
  • Ability to have access to a smartphone and be capable of using a mobile app for speech-based data collection.

Individuals with psychosis Exclusion Criteria:

  • Severe comorbid speech disorders (aphasia or severe stuttering) that prevent adequate speech recording.
  • Individuals who are not able or willing to understand the purpose and details of the investigation.

Citizens with psychiatric or somatic comorbidity, drug- or alcohol abuse will be allowed to participate, so that the sample will reflect the general population of citizens with psychosis and the study's endpoints will be generalizable.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • At risk of relapse

    Individuals at risk of psychotic relapse

    Other: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

  • Healthy controls

    Healthy participants will be used as controls

    Other: Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

Interventions

  • OtherWeekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.

    The intervention is a weekly online assessment of speech, to detect subtle characteristics of psychotic speech. These recordings are made through a speech data collection tool: a smartphone app with implemented tasks for the collection of behavioral response data (speech and self-report). Data is then transferred to a safe repository (TSD) to be analysed by an AI-based speech data analysis algorithm: a backend system will run the predictor code to calculate automatic relapse risk scores.

06

What researchers measure

Primary outcomes

  1. Feasibility: User adherence

    Proportion of users adhering to their allocated tasks. Task completion is automatically assessed for each user. A user is regarded as adherent, if they complete at least 33% of their tasks across all sessions.

    Time frame: From enrollment to the end of the study at 12 months

  2. Feasibility: Transcription quality

    Proportion of users for which high quality transcripts are produced. Transcription quality is measured by the Word Error Rate (WER) between Automated Speech Recognition (ASR) and human corrected transcripts. A user with an overall WER of at most 35% is regarded as having high quality transcripts

    Time frame: From enrollment to the end of the study at 12 months

  3. Feasibility: Usability of recordings

    Proportion of recordings that can be used by the AI algorithm. Usability of each record is assessed by HITL reviewers based on the three questions (i) has the user interpreted the question correctly, and (ii) is the audio (at least partially) audible and (iii) comprehensible. The three questions must both be answered with yes for the recording to be usable

    Time frame: From enrollment to the end of the study at 12 months

  4. Overall system usability

    Proportion of users rating the app as usable. Usability is evaluated using the System Usability Scale (SUS), providing a standardized usability score (range 0-100) based on a 10-item questionnaire. We regard a score of at least 70 as usable.

    Time frame: 6 months and 12 months

  5. Performance of the monitoring system for relapse prediction

    Assessed by the Area Under the Receiver Operating Characteristic Curve (AUC). Thresholds for relapse prediction will be explored as part of the analysis

    Time frame: From enrollment to the end of the study at 12 months

Secondary outcomes

  1. Provider-perceived usability and usefulness

    Provider-perceived usability and usefulness of the app will be assessed using the mHealth App Usability Questionnaire (MAUQ - Provider version). Scores will be reported by domain and overall

    Time frame: 6 months and 12 months

  2. Relapse Outcome 1

    Relapse rate, defined as the proportion of participants experiencing at least one relapse (rehospitalization) during the study period.

    Time frame: 6 months and 12 months

  3. Relapse Outcome 2

    Human-in-the-loop (HITL) relapse risk estimates and relapse incidence: HITL risk scores (range 0-1) will be categorized into low (0-0.2), medium (\>0.2-0.6), and high (\>0.6) risk levels. Descriptive analyses will assess the proportion of relapses within each category.

    Time frame: From enrollment to the end of the study at 12 months

  4. Relapse Outcome 3

    Clinical decision support system (CDSS) relapse risk estimates and relapse incidence: CDSS risk scores (range 0-1) will be categorized into low, medium, and high risk using the same thresholds. Descriptive analyses will assess relapse proportions per category.

    Time frame: From enrollment to the end of the study at 12 months

  5. Relapse Outcome 4

    Predictive performance of HITL relapse risk estimates will be evaluated using the area under the curve (AUC), with exploratory assessment of prediction thresholds.

    Time frame: From enrollment to the end of the study at 12 months

  6. Relapse Outcome 5

    Concordance between CDSS and HITL relapse risk estimates will be assessed by evaluating the level of agreement between algorithm-based and clinician-based risk scores.

    Time frame: From enrollment to the end of the study at 12 months

  7. Recordings Outcome 1

    Number of recordings per participant across all sessions.

    Time frame: From enrollment to the end of the study at 12 months

  8. Recordings Outcome 2

    Interpretation of question: has the user interpreted the question correctly? Yes or no. Per recording.

    Time frame: From enrollment to the end of the study at 12 months

  9. Recordings Outcome 3

    Audibility of audio: is the audio (at least partially) audible? Yes or no. Per recording.

    Time frame: From enrollment to the end of the study at 12 months

  10. Recordings Outcome 4

    Comprehensibility of audio: is the audio (at least partially) comprehensible? Yes or no. Per recording

    Time frame: From enrollment to the end of the study at 12 months

  11. Speech-based features

    Exploratory comparison analysis of speech-based features extracted using tools such as Prosogram or openSMILE.

    Time frame: From enrollment to the end of study at 12 months.

  12. Text-based features Outcome 1

    In addition, robust text-based features like speech rate and pause rate will be derived using common Python libraries for Natural Language Processing (NLP) like NLTK and spaCy.

    Time frame: From enrollment to the end of the study at 12 months.

  13. Text-based features Outcome 2

    WordNet will be used to analyze correctness of responses where appropriate (fluency task, story recall task, adapted Stroop task).

    Time frame: From enrollment to the end of the study at 12 months

  14. Neuroimaging-based features Outcome 1

    Exploratory comparison analysis of features extracted from structural magnetic resonance imaging (sMRI) data.

    Time frame: 6 months and 12 months

  15. Neuroimaging-based features Outcome 2

    Exploratory comparison analysis of features extracted from functional magnetic resonance imaging (fMRI) data.

    Time frame: 6 months and 12 months

  16. Neuroimaging-based features Outcome 3

    Exploratory comparison analysis of features extracted from Diffusion Tensor Imaging (DTI) data.

    Time frame: 6 months and 12 months

  17. Social and occupational function of participants Outcome 1

    Quality of life assessed with Quality of Life Scale (QoL). Assessed only in participants at risk of relapse

    Time frame: Baseline, 6 months and 12 months

  18. Social and occupational function of participants Outcome 2

    Global Assessment of Functioning Scale (GAF): measures how much a person's symptoms affect their day-to-day life on a scale of 0 to 100. Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

  19. Social and occupational function of participants Outcome 3

    Social and Occupational Functioning Assessment Scale (SOFAS): a global rating of current social and occupational functioning with scores ranging from 0 to 100. It differs from GAF by focusing on social and occupational functioning independent of the overall severity of the individual's psychological symptoms. Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

  20. Social and occupational function of participants Outcome 4

    Number of psychiatric admissions. Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

  21. Social and occupational function of participants Outcome 5

    Duration (in weeks) of psychiatric admissions. Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

  22. Social and occupational function of participants Outcome 6

    Rates of self-harm (including suicide, suicide attempts and aggressive incidents) assessed with the Social Dysfunction \& Aggression Scale (SDAS). Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

  23. Social and occupational function of participants Outcome 7

    Positive and Negative Syndrome Scale (PANSS): measure the prevalence of positive and negative syndromes in schizophrenia. Scores will be reported by dimension (positive, negative, and general psychopathology) and overall. Assessed only in participants at risk of relapse

    Time frame: 6 months and 12 months

07

Study locations

1 of 7 sites recruiting
  • National Institute of Mental Health
    Klecany, 250 67, Czechia
    Not yet recruiting
  • Newcastle Hospital and RCSI University of Medicine and Health Sciences
    Greystones, Wicklow A63 CD30, Ireland
    Not yet recruiting
  • University Medical Center Groningen
    Groningen, 9713, Netherlands
    Not yet recruiting
  • The Arctic University of Norway
    Tromsø, 9037, Norway
    Active, not recruiting

    Not enrolling at this site.

  • University Hospital Geneva and University of Geneva
    Geneva, Chêne-Bourg 1225, Switzerland
    Not yet recruiting
  • Psychiatric University Hospital Zurich and University of Zurich
    Zurich, 8032, Switzerland
    Recruiting
  • Dokuz Eylul University
    Izmir, Turkey (Türkiye)
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 36 months after the start.

Of 74 non-industry observational studies under Psychotic Disorders, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 124. This study's planned 36 months is below that.

Counting every sponsor, half of 76 studies reached it within 64 months; a quarter within 35 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Feb 9, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07397975
Lead sponsor
Philipp Homan
Responsible party
Philipp Homan (Prof. Dr. med. univ. Philipp Homan, PhD, University of Zurich) — Sponsor-investigator
First posted
Feb 9, 2026
Start date
Jan 29, 2026
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Feb 9, 2026

Study contacts

Philipp Homan, Prof. Dr. med. univ. PhD
Contact
philipp.homan@bli.uzh.ch
+41 58 384 33 65

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion